Over the years, the educational course before ICML has become a well-recognised programme for physicians and scientists with an interest in the diagnosis and treatment of haematological cancers. Oncology and haematology trainees are just as welcome as more experienced physicians looking for a refresher course. Participation of pathologists, radiation oncologists, and scientists with an interest in lymphoma is also appreciated allowing for a stimulating international gathering of colleagues from all over the world.
A particular feature of this course is the attendance cap (maximum 80) to emphasize the opportunity for a fruitful informal exchange of ideas, views, and experiences among the participants and with faculty.
Who should attend?
The target audience is post-graduate medical doctors at any stage of their clinical career, oncology/haematology trainees as well as more experienced clinicians, pathologists, and radiation oncologists with an interest in lymphoma.
Learning objectives
- Background knowledge of biology and molecular pathology of haematological cancers;
- Practice-oriented presentation of modern diagnostic tools;
- Essential perspective of clinical features of lymphoma entities;
- Comprehensive overview of the most relevant treatment options, covering also the “unmet needs” and the open questions.
A request for accreditation of the ICML-ESMO full immersion course “State of the Art in Malignant Lymphoma”, Lugano, Switzerland (14-16 June 2025), has been submitted to the European Accreditation Council for Continuing Medical Education (EACCME®) for European CME credits (ECMEC®s).
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The course has been also accredited with 15 category 1 ESMO-MORA points.
For any other information please contact course@icml.ch.